UNASSIGNED: This ethics-committee-approved, retrospective, multicenter, double-arm study was conducted across 10 facilities in the HCA Healthcare West Florida Division. Adult inpatients age 18 and older with confirmed COVID-19 and administered intravenous remdesivir from May 1, 2020, to July 31, 2020, were included. Exclusion criteria included patients less than 18 years of age, the concomitant use of hydroxychloroquine or tocilizumab for any indication, or an estimated glomerular filtration rate less than 30 milliliters per minute. The primary outcome of this study was in-patient all-cause mortality. Secondary outcomes included total length of stay, time to discharge, oxygen requirements, and number of ventilator days.
UNASSIGNED: A total of 217 patients from facilities in the HCA Healthcare West Florida Division were evaluated for inclusion. The primary outcome of all-cause mortality occurred in 34.9% of patients with symptom onset of fewer than 7 days versus 31.0% of patients with symptom onset of at least 7 days (P = .57). There were no statistical differences found among the secondary outcomes.
UNASSIGNED: Time since symptom onset did not result in a statistically significant difference in all-cause mortality in patients who received intravenous remdesivir for the treatment of COVID-19.
■这个伦理委员会批准,回顾性,多中心,在HCA医疗保健西佛罗里达分部的10个设施中进行了双臂研究。包括年龄在18岁及以上的确诊为COVID-19并从2020年5月1日至2020年7月31日静脉注射雷地韦的成年住院患者。排除标准包括18岁以下的患者,同时使用羟氯喹或托珠单抗治疗任何适应症,或估计肾小球滤过率小于30毫升/分钟。这项研究的主要结果是住院全因死亡率。次要结果包括总住院时间,放电时间,氧气需求,和呼吸机天数。
■对来自HCA医疗西佛罗里达分部机构的217名患者进行了纳入评估。症状发作少于7天的患者占34.9%,症状发作至少7天的患者占31.0%(P=0.57)。在次要结果之间没有发现统计学差异。
■自症状发作以来的时间并未导致接受静脉注射雷德西韦治疗COVID-19的患者全因死亡率的统计学差异。